

Greetings

The Sendai Conference was held for the first time in 2011, and we are grateful to all involved that we were able to hold the 12th Sendai Conference in 2025. In the last 14 years, the MS and NMOSD environment has changed dramatically, and many new drugs have become available. We aim to cure the disease by providing treatment tailored to the patient's condition, but the goal is still a long way off, and we need to work together with researchers and companies around the world to advance development, and I think the role of the Sendai Conference is by no means small.

The Sendai Conference was originally organized by the Department of Neurology at Tohoku University, but to ensure transparency in terms of income and expenses, and to optimize relationships with sponsoring companies, the NPO Japan Multiple Sclerosis Network was established in 2019, and the conference has continued as a project organized by this NPO. This year, we are again holding a seminar co-hosted by five companies: Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K., Biogen Japan Ltd., Alexion Pharma G.K., and Mitsubishi Tanabe Pharma Corporation. We plan to invite overseas experts to each seminar.

The aim of the Sendai Conference is to provide an opportunity for interaction with overseas experts. We have made sure that there is enough time in the program for questions and answers, and we will also hold a reception after the conference. We hope that you will take this opportunity to deepen your friendship with overseas experts and create opportunities for joint research. We look forward to receiving your abstract submissions.

Ichiro Nakashima

Chairperson of the Board of Directors, Japan Multiple Sclerosis Network

Professor, Division of Neurology, Tohoku Medical and Pharmaceutical University